KRW46,750.00
0.85% today
Korea, Sep 30, 08:11 am CET
ISIN
KR7302440003
Symbol
302440
Index

SK Bioscience Target price 2025 - Analyst rating & recommendation

SK Bioscience Classifications & Recommendation:

Buy
9%
Hold
36%
Sell
55%

SK Bioscience Price Target

Target Price KRW38,760.00
Price KRW46,800.00
Deviation
Number of Estimates 7
7 Analysts have issued a price target SK Bioscience 2026 . The average SK Bioscience target price is KRW38,760.00. This is lower than the current stock price. The highest price target is
KRW63,000.00 34.62%
register free of charge
, the lowest is
KRW30,300.00 35.26%
register free of charge
.
A rating was issued by 11 analysts: 1 Analysts recommend SK Bioscience to buy, 4 to hold and 6 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SK Bioscience stock has an average upside potential 2026 of . Most analysts recommend the SK Bioscience stock at Sale.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion KRW 267.55 628.63
27.59% 134.96%
EBITDA Margin -48.41% -0.92%
2,809.38% 98.10%
Net Margin -20.14% -9.31%
433.44% 53.77%

7 Analysts have issued a sales forecast SK Bioscience 2025 . The average SK Bioscience sales estimate is

KRW629b
Unlock
. This is
17.52% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
KRW697b 30.34%
Unlock
, the lowest is
KRW571b 6.82%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 KRW268b 27.59%
2025
KRW629b 134.96%
Unlock
2026
KRW705b 12.11%
Unlock
2027
KRW745b 5.77%
Unlock

7 Analysts have issued an SK Bioscience EBITDA forecast 2025. The average SK Bioscience EBITDA estimate is

KRW-5.8b
Unlock
. This is
94.95% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
KRW167b 245.65%
Unlock
, the lowest is
KRW-104b 9.06%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 KRW-130b 2,006.57%
2025
KRW-5.8b 95.53%
Unlock
2026
KRW22.0b 479.52%
Unlock
2027
KRW22.3b 1.27%
Unlock

EBITDA Margin

2024 -48.41% 2,809.38%
2025
-0.92% 98.10%
Unlock
2026
3.12% 439.13%
Unlock
2027
2.99% 4.17%
Unlock

7 SK Bioscience Analysts have issued a net profit forecast 2025. The average SK Bioscience net profit estimate is

KRW-58.5b
Unlock
. This is
11.01% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
KRW0.0 100.00%
Unlock
, the lowest is
KRW-89.4b 69.65%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 KRW-53.9b 341.43%
2025
KRW-58.5b 8.57%
Unlock
2026
KRW-35.0b 40.13%
Unlock
2027
KRW-35.2b 0.39%
Unlock

Net Margin

2024 -20.14% 433.44%
2025
-9.31% 53.77%
Unlock
2026
-4.97% 46.62%
Unlock
2027
-4.72% 5.03%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share KRW -697.93 -746.43
340.84% 6.95%
P/E negative
EV/Sales 4.73

7 Analysts have issued a SK Bioscience forecast for earnings per share. The average SK Bioscience EPS is

KRW-746.43
Unlock
. This is
11.13% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
KRW0.00 100.00%
Unlock
, the lowest is
KRW-1,140.72 69.84%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 KRW-697.93 340.84%
2025
KRW-746.43 6.95%
Unlock
2026
KRW-446.88 40.13%
Unlock
2027
KRW-448.61 0.39%
Unlock

P/E ratio

Current -70.20 144.68%
2025
-63.17 10.01%
Unlock
2026
-105.51 67.03%
Unlock
2027
-105.10 0.39%
Unlock

Based on analysts' sales estimates for 2025, the SK Bioscience stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.56 35.35%
2025
4.73 14.89%
Unlock
2026
4.22 10.80%
Unlock
2027
3.99 5.46%
Unlock

P/S ratio

Current 6.86 40.90%
2025
5.83 14.91%
Unlock
2026
5.20 10.80%
Unlock
2027
4.92 5.46%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today